PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Negative EBIT growth while RVPH is at 5.85%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-6.04%
Negative operating income growth while RVPH is at 7.11%. Joel Greenblatt would press for urgent turnaround measures.
-65.74%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-47.67%
Negative EPS growth while RVPH is at 7.69%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-53.82%
Negative diluted EPS growth while RVPH is at 7.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
12.14%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.50%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Negative OCF growth while RVPH is at 38.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.04%
Negative FCF growth while RVPH is at 38.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19589.97%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
63.13%
3Y OCF/share CAGR 1.25-1.5x RVPH's 53.59%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-19587.84%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-19245.92%
Negative 5Y net income/share CAGR while RVPH is 60.51%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
62.10%
3Y net income/share CAGR similar to RVPH's 58.01%. Walter Schloss would attribute it to shared growth factors or demand patterns.
30196.53%
Equity/share CAGR of 30196.53% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5954.03%
Equity/share CAGR of 5954.03% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
827.17%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Asset growth well under 50% of RVPH's 64.40%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-14.41%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.86%
We expand SG&A while RVPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.